Skip to content

JQ1 targeting BRD4 enhances cisplatin-induced pyroptosis via LDHA-mediated ROS release to potentially overcome chemoresistance in bladder cancer.

Nov 2026 · Biochimica et Biophysica Acta - Molecular Basis of Disease · pp. 168510 · 0 citations · 45 references
Medicine

Abstract

Cisplatin-based chemotherapy is a cornerstone treatment for muscle-invasive bladder cancer (MIBC), yet resistance to cisplatin and its adverse effects limit clinical efficacy. Novel strategies to sensitize tumors to cisplatin are urgently needed. As a chromatin reading protein, BRD4 can regulate gene expression and play an important role in the occurrence and development of tumors. JQ1 as a well-known BRD4 inhibitor, can cause cell apoptosis and is mainly used in the field of hematological tumors. Its clinical value in bladder cancer (BC) had not yet been fully clarified. Through bioinformatics and clinical cohort analyses, we identified bromodomain-containing protein 4 (BRD4) as a potential regulator of chemoresistance in BC. High BRD4 expression correlated with poor prognosis and cisplatin resistance in BC patients. BRD4 knockdown or pharmacological inhibition by JQ1 significantly suppressed BC cell proliferation, migration, and invasion, and enhanced sensitivity to cisplatin. Mechanistically, JQ1 disrupted the BRD4-LDHA interaction, promoting LDHA cytoplasmic accumulation, which led to reactive oxygen species (ROS) generation and then activated GSDME and pyroptosis. In vivo, the combination of low-dose JQ1 and cisplatin significantly reduced tumor burden and prolonged survival, without systemic toxicity. These findings provided the theoretical support of the innovative strategy of Cis-JQ1 combination therapy for BC, contributing to addressing the clinical challenge of chemoresistance in BC.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.